| HIV Infection |
1 |
1 |
| COVID-19 |
0 |
0.92 |
| Clinical Guidelines |
0 |
0.77 |
| Pregnancy |
0 |
0.77 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.65 |
| Lipids Management |
0 |
0.58 |
| Tuberculosis |
0 |
0.58 |
| Hepatitis C Virus |
0 |
0.57 |
| Fungal Infection |
0 |
0.48 |
| Child |
0 |
0.46 |
| Europe |
0 |
0.31 |
| Hepatitis |
0 |
0.29 |
| COVID-19 Treatment |
0 |
0.27 |
| Obesity |
0 |
0.22 |
| AIDS |
0 |
0.2 |
| Addiction |
0 |
0.16 |
| Social Determinants of Health |
0 |
0.14 |
| Cardiovascular Risk Management |
0 |
0.1 |
| Drug Interaction |
0 |
0.1 |
| Heart Failure (HF) |
0 |
0.1 |
| Pandemic |
0 |
0.1 |
| Prophylaxis |
0 |
0.1 |
| Sexual Health |
0 |
0.1 |
| Hypertension |
0 |
0.09 |
| Anxiety Disorder |
0 |
0.07 |
| Chronic Kidney Disease |
0 |
0.07 |
| NHS |
0 |
0.07 |
| Renal Disease |
0 |
0.07 |
| Renal Failure |
0 |
0.07 |
| Adolescent Medicine |
0 |
0.05 |
| Anxiety |
0 |
0.05 |
| Anxiolytic |
0 |
0.05 |
| Birth |
0 |
0.05 |
| Breastfeeding |
0 |
0.05 |
| Cancer |
0 |
0.05 |
| Cardiovascular disease |
0 |
0.05 |
| Concerns of Elderly |
0 |
0.05 |
| Cryptococcosis |
0 |
0.05 |
| Dorsum |
0 |
0.05 |
| Drug-Resistant Tuberculosis |
0 |
0.05 |
| Epidemiology |
0 |
0.05 |
| Geriatrics |
0 |
0.05 |
| Health Care Services |
0 |
0.05 |
| Heart |
0 |
0.05 |
| HIV Transmission |
0 |
0.05 |
| Hormonal Therapy |
0 |
0.05 |
| Hypercholesterolemia |
0 |
0.05 |
| Immunization |
0 |
0.05 |
| Kidney |
0 |
0.05 |
| Meningitis |
0 |
0.05 |
| Newborn |
0 |
0.05 |
| Opportunistic Infection |
0 |
0.05 |
| Protease Inhibitor |
0 |
0.05 |
| Transgender |
0 |
0.05 |
| Meningococcal Disease |
0 |
0.04 |
| Pneumonia |
0 |
0.04 |